Koopmanschap M A
Institute for Medical Technology Assessment (IMTA), Erasmus University Rotterdam, The Netherlands.
Pharmacoeconomics. 1998 Aug;14(2):143-8. doi: 10.2165/00019053-199814020-00001.
A sample of cost-of-illness (COI) studies was reviewed, which included studies for specific diseases ('specific' studies) as well as those for the entire range of diseases ('general' studies). Theoretically, COI studies may deliver suitable information for health policy and rational healthcare spending. In practice, however, the informative value of 'specific' prevalence-based COI studies is very limited. A static picture of costs is presented in these studies, as trends in costs are not being described or explained by factors such as demography, epidemiology and technology. No practical link is offered between COI estimates and economic evaluation. Incidence-based COI studies can provide more relevant information for economic evaluation studies. It appears more useful to perform general COI studies, as these provide comparable estimates of disease costs and put cost estimates in a total healthcare perspective. Compared with specific COI studies, general COI studies better facilitate the analysis and projection of trends in costs, for example due to aging.
对一组疾病成本（COI）研究进行了综述，其中包括针对特定疾病的研究（“特定”研究）以及针对所有疾病范围的研究（“一般”研究）。从理论上讲，疾病成本研究可为卫生政策和合理的医疗保健支出提供合适的信息。然而，在实践中，基于患病率的“特定”疾病成本研究的信息价值非常有限。这些研究呈现的是成本的静态情况，因为成本趋势并未通过人口统计学、流行病学和技术等因素进行描述或解释。疾病成本估计与经济评估之间没有建立实际联系。基于发病率的疾病成本研究可为经济评估研究提供更相关的信息。进行一般疾病成本研究似乎更有用，因为这些研究提供了可比的疾病成本估计，并从整体医疗保健角度给出成本估计。与特定疾病成本研究相比，一般疾病成本研究更有助于分析和预测成本趋势，例如由于老龄化导致的成本趋势。
